Navigation Links
Resverlogix Announces Closing of Debt Redemption
Date:10/17/2008

TSX Exchange Symbol: RVX

CALGARY, Oct. 17 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that the Toronto Stock Exchange has approved Resverlogix's previous announcement on October 15, 2008 regarding the redeeming of US $10 million of its remaining US $17.3 million debenture. The remaining balance of the debenture including accrued interest earned to October 14, 2008 is US $7.89 million.

To assist shareholders with understanding the salient and beneficial points to this amendment Resverlogix will post key facts to SEDAR.

Rodman & Renshaw, LLC served as an advisor to the company.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's disease and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit http://www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.


'/>"/>
SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
2. Resverlogix is Presenting at IAS HDL Workshop
3. Resverlogix Honoured with World Economic Forum Technology Pioneer Award
4. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
5. Resverlogix Share Option Extension
6. Resverlogix Notice of Conference Call & Webcast
7. /C O R R E C T I O N from Source -- Resverlogix Corp./
8. Industry Leaders Select Resverlogixs RVX-208
9. Resverlogixs Lead Drug Featured in Key Scientific Publication
10. Jan Gray Joins Resverlogix Board of Directors
11. Resverlogix Notice of Conference Call & Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... , May 20, 2013  (PSHR) Pacific ... naturally based products across a broad range of ... has retained investor relations firm, BlueWater Advisory Group, ... return to trading process, and to direct the ... initiation. Matthew Mills ...
(Date:5/20/2013)... , May 20, 2013   BioHealth ... focusing on commercializing market-relevant biohealth innovations and increasing ... Maryland , today announced its selection of ... (EIR) for BHI at the National Institutes of ... Institute (NHLBI). Dr. Aiyar will help advance ...
(Date:5/20/2013)... May 20, 2013 Interventional cardiologist Tony ... General Hospital (AGH) Cardiovascular Institute have helped pioneer ... artery disease (CAD) over the past three decades, ... balloon angioplasty and coronary artery stent implantation. , Today, ... play a prominent role in the study of a ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 Kitware, a ... visualization tool that enables the exploration of hospital ... created in response to the recent release of “Medicare ... the top 100 most-billed procedures from the Centers for ... costs for similar procedures at hospitals across the country ...
Breaking Biology Technology:Pacific Shore Holdings Retains Investor Relations Firm 2BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 2BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 3BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 4Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 2Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 3Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 4Kitware Enables Interactive Exploration of CMS Medicare Data 2
... December 3 On,November 28, Essilor cancelled 1,600,000 shares, ... dilutive impact of Oceane bond conversions and,the Company,s stock ... These latest cancellations concerned shares acquired under the 6.9,million ... on July,15, 2008 to offset the dilutive impact of ...
... Dec. 2 Transgenomic,Inc. (OTC Bulletin Board: ... Board: PWRM) today announced that Transgenomic has ... rights for Power3 Medical,s Neurodegenerative,Biomarkers, which include ... disease. Transgenomic plans to offer NuroPro(R) ...
... 2 Bionovo, Inc.,(Nasdaq: BNVI ), a pharmaceutical company ... the areas of women,s health and,cancer, announced that Isaac Cohen, Chairman ... at the 20th Annual Piper Jaffray Health,Care Conference at 8 a.m. ... at,the New York Palace Hotel in New York City. , ...
Cached Biology Technology:Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics 2Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics 3Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics 4Bionovo to Present at the Piper Jaffray Healthcare Conference 2
(Date:5/17/2013)... Atlanta residents of all ages will celebrate the ... impact on our daily lives during the inaugural ... engineers and educators from local museums, corporations, K-12 ... than 40 different events for children and adults ... http://atlantasciencefestival.org . , The annual Atlanta ...
(Date:5/17/2013)... in Efficient and Sustainable Global Logistics Operations) is aiming ... the efficiency of intermodal loading systems and the boosting ... 29 European organisations with experience in the logistics sector ... totalling 17,000,000 and a duration of three and a ... develop the semantic components and ontologies shared by the ...
(Date:5/17/2013)... team of scientists using a new X-ray method recorded ... frog embryo in greater detail than ever before., This ... and the search for new treatments for genetic diseases., ... Technologie in Germany, in collaboration with the Advanced Photon ... Laboratory, released the most precise depiction ever of the ...
Breaking Biology News(10 mins):First Atlanta Science Festival set for 2014 2New logistics services that will cut energy consumption and CO2 emissions 2New X-ray method shows how frog embryos could help thwart disease 2
... birth to develop the ability to determine sunrise and ... of Chicago shows. The research sheds new light ... behaviors, according to Brian Prendergast, associate professor in psychology ... paper published April 27 in the journal PLoS One. ...
... to investigate such things as how Pacific Northwest forests ... by pests and diseases is being pruned back to ... located in a 500-year-old forest near Stevenson in southwest ... Washington, the Forest Service,s Pacific Northwest Research Station and ...
... An international team of scientists, led by researchers at ... have developed a new method for discerning the functions ... functional networks that reveal how gene products interact to ... in the April 29 issue of the journal Cell. ...
Cached Biology News:From the beginning, the brain knows the difference between night and day 2Era of canopy crane ending; certain research and education activities remain 2Era of canopy crane ending; certain research and education activities remain 3As the worm turns, its secrets are revealed 2
...
Bovine Renal Artery Endothelial Cells (BRAEC) (>500,000 cells)...
RECK (F-20)...
... polyclonal to Peroxiredoxin 1 Peroxiredoxin ... whose mammalian members have been known ... and apoptosis. Many isoforms (about 50 ... amino acid sequence homology, particularly amino-terminal ...
Biology Products: